Evidence map›Paper›PMID 42310173›Full record

ArticleEJNMMI research2026

First-in-human radiation dosimetry of the GRPR antagonist [

Annie Bjäreback, Ulrika Estenberg, Antonios Tzortzakakis, Rimma Axelsson, Chunde Li, Renske Altena, Thuy A Tran, Cecilia Hindorf

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06147362 (68Ga-NOTA-PEG2-RM26 PET/CT), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06147362 phase1unknown statusnot on this map

68Ga-NOTA-PEG2-RM26 PET/CT: Tracer Biodistribution and Uptake in Different Kinds of Cancer With Gastrin-Releasing Peptide Receptor (GRPR) Overexpression

TypeinterventionalSponsorKarolinska University HospitalRan2022 to 2023Enrolled50ConditionsCancerArms68Ga-NOTA-PEG2-RM26
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Annie BjärebackDepartment of Nuclear Medicine and Medical Physics, Section Nuclear Medicine Huddinge, Karolinska University Hospital, Stockholm, Sweden. annie.bjareback@ki.se.ORCID http://orcid.org/0009-0007-0442-7625
Ulrika EstenbergDepartment of Nuclear Medicine and Medical Physics, Section Nuclear Medicine Huddinge, Karolinska University Hospital, Stockholm, Sweden.
Antonios TzortzakakisDepartment of Nuclear Medicine and Medical Physics, Section Nuclear Medicine Huddinge, Karolinska University Hospital, Stockholm, Sweden.
Rimma AxelssonDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.
Chunde LiDepartment of Oncology, Södersjukhuset, Stockholm, Sweden.
Renske AltenaDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Thuy A TranDepartment of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.
Cecilia HindorfDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundGastrin-releasing peptide receptor (GRPR) is overexpressed in several malignant tumours, while its physiological expression in major organs, except for pancreas, is low. GRPR is therefore an interesting target in nuclear medicine. The GRPR-binding ligand, [

resultsThe pancreas, liver, spleen, kidney parenchyma, gall bladder, urinary bladder contents and cortical bone were identified as source organs/regions. Results using OLINDA/EXM 2.3.0 dosimetry software showed that pancreas was the organ that received the highest absorbed dose, 110 ± 43 µGy/MBq, followed by the urinary bladder wall, 100 ± 36 µGy/MBq, and the kidneys, 31 ± 11 µGy/MBq. The osteogenic cells received 15 ± 7 µGy/MBq. The median (range) of the total excreted activity through urine was 56% (43-75%) of the injected activity in 4h. The effective dose (ICRP 103) from an injection of [

conclusionA standard person of 70kg receiving 140MBq of [

trial registrationClinicaltrials.gov, NCT06147362, Registered 17 November 2023 - Retrospectively registered, https://www. CLINICALTRIALS: gov/study/NCT06147362.

Indexed as

68GaBreast cancerFirst-in-humanGastrin releasing peptide receptorGRPRPETPositron emission tomographyProstate cancerRadiation dosimetry

Identifiers

PMID42310173
PMCPMC13275974

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.